Advertisement
New Zealand markets open in 2 hours 56 minutes
  • NZX 50

    11,557.21
    -121.47 (-1.04%)
     
  • NZD/USD

    0.6123
    +0.0005 (+0.09%)
     
  • ALL ORDS

    7,895.90
    -39.80 (-0.50%)
     
  • OIL

    78.03
    -1.20 (-1.51%)
     
  • GOLD

    2,364.10
    0.00 (0.00%)
     

Veru Reports Fiscal 2023 First Quarter Financial Results

Veru Inc.
Veru Inc.

Sabizabulin for moderate to severe COVID-19 under review for potential emergency authorization by multiple global regulatory agencies

Presented late-breaker oral presentation at IDWeek; sabizabulin treatment resulted in 81.2% relative reduction in deaths compared to the placebo in the WHO 4 subset group

Company to host conference call and webcast today at 8:00 a.m. ET

MIAMI, FL, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced financial results for its fiscal 2023 first quarter and provided a business update.

ADVERTISEMENT

“We have been busy seeking emergency authorization for sabizabulin for the treatment of hospitalized moderate to severe COVID-19 patients at high risk for ARDS with major global regulatory bodies,” said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru. “Our U.S. and international commercial teams are on standby. We are actively enrolling subjects in our advanced breast and prostate cancer Phase 3 clinical studies. Further, we have put in place a multi-pronged strategy to increase revenues from our sexual health program which appears to be successful as Q2 FY 2023 sales are significantly improving. As we await regulatory decisions, we have implemented measures to prudently conserve our cash, and we will provide an update once we are able to determine our path forward.”

Infectious Disease Program Updates
Sabizabulin, a Novel Oral Microtubule Disruptor, for the Treatment of Hospitalized Moderate to Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)

Sabizabulin for the treatment of COVID-19 is currently under regulatory review for potential emergency authorization by U.S. Food and Drug Administration (FDA), European Union’s European Medicines Agency (EMA), United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA), Australia’s Therapeutic Goods Administration (TGA), Canada’s Health Canada, South Korea’s Ministry of Food and Drug Safety (MFDS), and Switzerland’s Swissmedic. With respect to Europe, if the EMA authorizes sabizabulin for emergency use under Article 18, then individual EU nations may decide to authorize sabizabulin in their respective countries.

In October 2022, Phase 3 data of sabizabulin for the treatment of COVID-19 was presented as a late-breaker at IDWeek (Infectious Disease Week) 2022. Clinical highlights from the presentation include statistically and clinically significant reductions in mortality with sabizabulin treatment resulting in a 22.4 absolute percentage point and 81.2% relative reduction in deaths compared to the placebo (p=0.0090) in a subset analysis of hospitalized moderate to severe WHO-4 COVID-19 patients at high risk for ARDS.

Oncology Program Updates
Enobosarm, a Novel Oral Selective Androgen Receptor Targeting Agonist, and Abemaciclib, a CDK 4/6 Inhibitor, Combination Therapy for the 2nd Line Treatment of AR+ER+HER2- Metastatic Breast Cancer

Enrollment has been ongoing in the Phase 3 multicenter, open label, randomized (1:1), active control ENABLAR-2 trial to evaluate the combination of enobosarm and abemaciclib for the treatment of AR+ER+HER2- metastatic breast cancer. We have a collaboration and supply agreement with Eli Lilly and Company for this trial.

Enobosarm for the 3rd Line Treatment of AR+ER+HER2- Metastatic Breast Cancer

Enrollment has been ongoing in the Phase 3 multicenter, international, open label, randomized (1:1) ARTEST trial to evaluate enobosarm for the treatment of AR+ER+HER2- metastatic breast cancer.

Sabizabulin for the Treatment of Metastatic Castration and Androgen Receptor Targeting Agent Resistant Prostate Cancer

Enrollment has been ongoing in the Phase 3 VERACITY open label, randomized (2:1), multicenter trial to evaluate sabizabulin 32mg for the treatment of chemotherapy naïve men with metastatic castration resistant prostate cancer who have tumor progression after previously receiving at least one androgen receptor targeting agent.

VERU-100, a Novel Proprietary Long-Acting Gonadotropin-Releasing Hormone (GnRH) Antagonist Peptide 3-Month Subcutaneous Depot Formulation, for Androgen Deprivation Therapy of Advanced Prostate Cancer

Enrollment has been ongoing in the Phase 2 clinical dose finding trial to evaluate VERU-100 for the treatment of androgen deprivation therapy in patients with advanced prostate cancer.

Urev - Sexual Health Program Updates
FC2 Female Condom/Internal Condom®

The Company markets and sells the FC2 Female Condom®, an FDA-approved product for dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.

ENTADFI™ (finasteride and tadalafil) capsules for oral use, a New Treatment for Benign Prostatic Hyperplasia (BPH)

The Company markets ENTADFI™, an FDA-approved oral, once daily product for benign prostatic hyperplasia (BPH) for men with an enlarged prostate experiencing the signs and symptoms of BPH for up to 26 weeks.

First Quarter Financial Summary: Fiscal 2023 vs Fiscal 2022

  • Net revenues decreased to $2.5 million from $14.1 million

  • Gross profit decreased to $0.7 million from $11.8 million

  • Research and development expenses increased to $18.7 million from $10.1 million

  • Selling, general and administrative expenses increased to $17.5 million from $6.7 million

  • Operating loss was $35.6 million versus $5.0 million

  • Net loss was $36.8 million, or $0.46 per share, compared to $6.4 million, or $0.08 per share

Balance Sheet Information

  • Cash and cash equivalents were $46.9 million as of December 31, 2022 versus $80.2 million as of September 30, 2022

  • Net accounts receivable were $3.9 million as of December 31, 2022 versus $3.6 million as of September 30, 2022

Event Details
The audio webcast will be accessible under “Investor Kit” in the Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. An archived version of the audio webcast will be available for replay on the Company’s website for approximately three months. A telephonic replay will be available on February 9, 2023 at approximately 12:00 p.m. ET by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) passcode 9127050 for one week.

About Veru Inc.
Veru is a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology. The Company’s infectious disease development program includes sabizabulin, an oral microtubule disruptor, for the treatment of hospitalized moderate to severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS). In the final analysis of the Phase 3 trial, treatment with sabizabulin 9 mg once daily resulted in a clinically meaningful and statistically significant 51.6% relative reduction in deaths compared to placebo. Sabizabulin for COVID-19 is currently under regulatory review for potential emergency or conditional authorization by U.S. FDA, European Union’s EMA, United Kingdom’s MHRA, Australia’s TGA, Canada’s Health Canada, South Korea’s MFDS, and Switzerland’s Swissmedic.

The Company’s breast cancer development portfolio comprises enobosarm, a selective androgen receptor targeting agonist, and sabizabulin. Veru’s oncology program also includes product candidates in development for the treatment of prostate cancer: sabizabulin, VERU-100, a long-acting GnRH antagonist and zuclomiphene citrate, an oral nonsteroidal estrogen receptor agonist.

The Company’s commercial sexual health program, Urev, has 2 FDA-approved products, including FC2 Female Condom® (internal condom), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections, which is sold in the U.S. and globally and ENTADFI™ (finasteride and tadalafil) capsules for oral use, a new treatment for benign prostatic hyperplasia.

Forward-Looking Statements
The statements in this release that are not historical facts are “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release include statements regarding: whether the Company will successfully develop or commercialize any drug in the infectious disease area and whether any such drug will serve a potentially life-saving unmet need; whether the Company’s infections disease franchise will generate any commercially available product and whether it will expand sabizabulin or any other compound beyond the potential treatment of certain COVID-19 patients; whether and when the Company will receive an emergency use authorization or any approval from FDA or from any regulatory authority outside the U.S. for sabizabulin for certain COVID-19 patients; whether and when sabizabulin will become an available treatment option for certain COVID-19 patients in the U.S. or anywhere outside the U.S.; whether any additional efficacy or safety clinical studies of sabizabulin for certain COVID-19 patients will be required by the FDA or any other regulatory authority as a condition to any authorization or as a post-authorization requirement;  whether the Company will have sufficient supply of sabizabulin or sufficient commercial resources to meet demand, if an emergency use authorization or other approval is granted in the U.S. or in any other country; whether the Company will secure any advance purchase agreement with any government; whether the current and future clinical development and results will demonstrate sufficient efficacy and safety and potential benefits to secure FDA approval of any of the Company’s other drug candidates; whether the drug candidates will be approved for the targeted line of therapy; the anticipated design and scope of clinical studies and FDA acceptance of such design and scope; whether any regulatory pathways, including the accelerated Fast Track designations, to seek FDA approval for sabizabulin, enobosarm or any of the Company’s drug candidates are or will continue to be available; whether the expected commencement and timing of the Company’s clinical studies, including the Phase 3 ENABLAR-2 study, the sabizabulin monotherapy Phase 2b clinical study for 3rd line treatment of metastatic breast cancer, and the Phase 2 registration clinical study for VERU-100 will be met; when clinical results from the ongoing clinical studies will be available, whether sabizabulin, enobosarm, VERU-100, or zuclomiphene will serve any unmet need or, what dosage, if any, might be approved for use in the U.S. or elsewhere, and also statements about the potential, timing and efficacy of the rest of the Company’s development pipeline, and the timing of the Company’s submissions to FDA and FDA’s review of all such submissions; whether ENTADFI will be commercialized successfully, the Company will grow sales of ENTADFI or the Company will be able to successful partner with any other entity to grow sales of ENTADFI; whether the telemedicine customers for FC2 will return to historical ordering patterns or increase their purchases of FC2 at all; whether the Company’s current cash will be sufficient to fund its planned or expected operations, especially if any authorizations for sabizabulin for certain COVID-19 patients are not obtained and whether the Company may need to raise capital; and whether any of the specified clinical trials will be suspended, modified or terminated as the Company seeks to conserve cash. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the development of the Company’s product portfolio and the results of clinical studies possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical studies and the ability to enroll subjects in accordance with planned schedules; the ability to fund planned clinical development; the timing of any submission to the FDA or any other regulatory authority and any determinations made by the FDA or any other regulatory authority; the possibility that as vaccines become widely distributed the need for new COVID-19 treatment candidates may be reduced or eliminated; government entities possibly taking actions that directly or indirectly have the effect of limiting opportunities for sabizabulin as a COVID-19 treatment, including favoring other treatment alternatives or imposing price controls on COVID-19 treatments; the Company’s existing products, including FC2 and ENTADFI and, if authorized, sabizabulin, and any future products, if approved, possibly not being commercially successful; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical studies, supply chain and other third-party providers, commercial efforts, and business development operations; the ability of the Company to obtain sufficient financing on acceptable terms when needed to fund development and operations; demand for, market acceptance of, and competition against any of the Company’s products or product candidates; new or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions; changes in regulatory practices or policies or government-driven healthcare reform efforts, including pricing pressures and insurance coverage and reimbursement changes; the Company’s ability to successfully commercialize any of its products, if approved; risks relating to the Company's development of its own dedicated direct to patient telemedicine and telepharmacy services platform, including the Company's lack of experience in developing such a platform, potential regulatory complexity, and development costs; the Company’s ability to protect and enforce its intellectual property; the potential that delays in orders or shipments under government tenders or the Company’s U.S. prescription business could cause significant quarter-to-quarter variations in the Company’s operating results and adversely affect its net revenues and gross profit; the Company’s reliance on its international partners and on the level of spending by country governments, global donors and other public health organizations in the global public sector; the concentration of accounts receivable with our largest customers and the collection of those receivables; the Company’s production capacity, efficiency and supply constraints and interruptions, including potential disruption of production at the Company’s and third party manufacturing facilities and/or of the Company’s ability to timely supply product due to labor unrest or strikes, labor shortages, raw material shortages, physical damage to the Company’s and third party facilities, COVID-19 (including the impact of COVID-19 on suppliers of key raw materials), product testing, transportation delays or regulatory actions; costs and other effects of litigation, including product liability claims; the Company’s ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company’s ability to successfully integrate acquired businesses, technologies or products; and other risks detailed from time to time in the Company’s press releases, shareholder communications and Securities and Exchange Commission filings, including the Company’s Form 10-K for the fiscal year ended September 30, 2022 and subsequent quarterly reports on Form 10-Q. These documents are available on the “SEC Filings” section of our website at www.verupharma.com/investors. The Company disclaims any intent or obligation to update these forward-looking statements.

Investor Contact:
Samuel Fisch
Executive Director, Investor Relations and Corporate Communications
Email: veruinvestor@verupharma.com

Media Contact:
Hannah Gendel
Manager, Corporate Communications
Email: media@verupharma.com

FINANCIAL SCHEDULES FOLLOW

Veru Inc.
Condensed Consolidated Balance Sheets
(unaudited)

 

 

 

 

 

 

 

December 31,

 

September 30,

 

2022

 

2022

 

 

 

 

 

 

Cash and cash equivalents

$

46,927,187

 

$

80,190,675

Accounts receivable, net

 

3,864,310

 

 

3,550,895

Inventories, net

 

8,732,627

 

 

8,618,944

Prepaid expenses and other current assets

 

13,484,521

 

 

12,408,960

Total current assets

 

73,008,645

 

 

104,769,474

 

 

 

 

 

 

Plant and equipment, net

 

1,425,970

 

 

1,185,766

Operating lease right-of-use assets

 

4,600,783

 

 

4,786,915

Deferred income taxes

 

13,052,163

 

 

12,965,985

Intangible assets, net

 

3,959,524

 

 

3,977,381

Goodwill

 

6,878,932

 

 

6,878,932

Other assets

 

856,435

 

 

1,561,564

Total assets

$

103,782,452

 

$

136,126,017

 

 

 

 

 

 

Accounts payable

$

10,566,962

 

$

22,003,394

Accrued research and development costs

 

12,678,176

 

 

9,071,503

Accrued expenses and other current liabilities

 

15,146,618

 

 

9,193,637

Residual royalty agreement liability, short-term portion

 

1,688,691

 

 

1,169,095

Total current liabilities

 

40,080,447

 

 

41,437,629

 

 

 

 

 

 

Residual royalty agreement liability, long-term portion

 

10,550,764

 

 

9,656,441

Operating lease liability, long-term portion

 

3,963,202

 

 

4,093,667

Other liabilities

 

89,181

 

 

99,644

Total liabilities

 

54,683,594

 

 

55,287,381

 

 

 

 

 

 

Total stockholders' equity

 

49,098,858

 

 

80,838,636

Total liabilities and stockholders' equity

$

103,782,452

 

$

136,126,017

 

 

 

 

 

 

Veru Inc.
Condensed Consolidated Statements of Operations
(unaudited)

 

 

 

 

 

 

 

Three Months Ended
December 31,

 

2022

 

 

2021

 

 

 

 

 

 

 

Net revenues

$

2,507,794

 

 

$

14,135,132

 

 

 

 

 

 

 

Cost of sales

 

1,805,739

 

 

 

2,293,050

 

 

 

 

 

 

 

Gross profit

 

702,055

 

 

 

11,842,082

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

Research and development

 

18,744,349

 

 

 

10,081,161

 

Selling, general and administrative

 

17,545,865

 

 

 

6,723,206

 

Total operating expenses

 

36,290,214

 

 

 

16,804,367

 

 

 

 

 

 

 

Operating loss

 

(35,588,159

)

 

 

(4,962,285

)

 

 

 

 

 

 

Non-operating expenses

 

(1,322,298

)

 

 

(1,303,066

)

 

 

 

 

 

 

Loss before income taxes

 

(36,910,457

)

 

 

(6,265,351

)

 

 

 

 

 

 

Income tax (benefit) expense

 

(68,278

)

 

 

114,655

 

 

 

 

 

 

 

Net loss

$

(36,842,179

)

 

$

(6,380,006

)

 

 

 

 

 

 

Net loss per basic and diluted common shares outstanding

$

(0.46

)

 

$

(0.08

)

 

 

 

 

 

 

Basic and diluted weighted average common shares outstanding

 

80,558,670

 

 

 

80,023,168

 


Veru Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)

 

 

 

 

 

 

 

Three Months Ended
December 31,

 

2022

 

 

2021

 

 

 

 

 

 

 

Net loss

$

(36,842,179

)

 

$

(6,380,006

)

 

 

 

 

 

 

Adjustments to reconcile net loss to net cash used in operating activities

 

6,407,640

 

 

 

2,650,481

 

 

 

 

 

 

 

Changes in operating assets and liabilities

 

(4,099,489

)

 

 

(4,928,267

)

 

 

 

 

 

 

Net cash used in operating activities

 

(34,534,028

)

 

 

(8,657,792

)

 

 

 

 

 

 

Net cash (used in) provided by investing activities

 

(285,565

)

 

 

2,197,791

 

 

 

 

 

 

 

Net cash provided by financing activities

 

1,556,105

 

 

 

204,427

 

 

 

 

 

 

 

Net decrease in cash

 

(33,263,488

)

 

 

(6,255,574

)

 

 

 

 

 

 

Cash at beginning of period

 

80,190,675

 

 

 

122,359,535

 

 

 

 

 

 

 

Cash at end of period

$

46,927,187

 

 

$

116,103,961